List of Vizamyl drug patents
Vizamyl is owned by Ge Healthcare.
Vizamyl contains Flutemetamol F-18.
Vizamyl has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vizamyl are:
- US8691185
- US7351401
Vizamyl was authorised for market use on 25 October, 2013.
Vizamyl is available in injectable;intravenous dosage forms.
Vizamyl can be used as diagnostic radioimaging.
The generics of Vizamyl are possible to be released after 16 September, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7351401 | GE HEALTHCARE | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition |
Jan, 2023
(3 days ago) | |
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(1 year, 3 months from now) | |
| US7270800 | GE HEALTHCARE | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Sep, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691185 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
Jan, 2023
(3 days ago) | |
| US8916131 | GE HEALTHCARE | Radiopharmaceutical composition |
Sep, 2028
(5 years from now) | |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
Dosage: INJECTABLE;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic